New became the norm at Cryoport this year. The company announced new partnerships, new product lines, and new services seemingly every week. On top of these exciting developments were notable milestones in earnings and growth. Here, we share a quick recap of our biggest moments in 2019 – but please pardon us if we’re brief, as we’re busy working on what’s next.
There is no question that the groundbreaking treatments being developed in Cell & Gene Therapy (CGT) are fundamentally changing the way patient care is managed around the world. As with most revolutionary breakthroughs in medicine or any other industry, the supply chain is critically important. These revolutionary therapies only have value if you can effectively get them to the patients, or in the case of CGT, into the patient’s vein. Furthermore, CGT treatments are extremely fragile and require weeks to develop in multiple facilities. It cannot be stressed enough that a fail-proof supply chain is necessary.
